Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join


Oct 19, 2021 10:00 AM - Oct 20, 2021 5:00 PM

(US Eastern Standard Time)

DIA Canadian Annual Meeting

The Canadian Annual Meeting now includes a track for Pharmacovigilence and Risk Management Strategies!


Short Course: October 18
Meeting: October 19-20

The DIA Annual Canadian Meeting will deliver a comprehensive overview of the current biopharma and device landscape in Canada, while sharing insights into Canada’s broader role in global healthcare product development. From policy updates and priorities shared directly from Health Canada, to sessions on international work sharing and partnerships, to key regulatory, clinical, and safey considerations for drugs and devices, you will have the exclusive opportunity to address the current issues and opportunities in Canada and across the globe. This meeting presents three tracks: Regulatory, Clinical, and Pharmacovigilance (NEW). Our new pharmacovigilance track, previously its own meeting, broadens the scope of this meeting and will provide additional insights, education and knowledge sharing for our attendees to discuss and analyze the relevant challenges and opportunities for professionals working in the field in Canada.


Want to learn more about DIA Canadian Annual Meeting? You've come to the right site!


Highlights & Features

Who should attend?

Professionals in pharmaceutical and device industries, regulatory agencies, and academia involved in:

  • Clinical Data Management/eClinical
  • Comparative Effectiveness/Health Technology Assessment
  • Clinical Safety/Pharmacovigilance
  • Clinical Research
  • Document Management/eSubmissions
  • Medical Communications
  • Outsourcing
  • Project Management
  • Public Policy/Law/Corporate Compliance
  • Quality Assurance Control
  • Regulatory Affairs
  • Research and Development
  • Statistics

Program Committee

  • Marcia  Bailey, BSN, MHS, RN
    Marcia Bailey, BSN, MHS, RN Safety Evaluation and Risk Management Scientific Director
    GSK, Canada
  • Marilyne  Chamoun, MSc
    Marilyne Chamoun, MSc Senior Scientific Evaluator, Marketed Pharmaceuticals Bureau
    Health Canada, Canada
  • Mandy  Collier
    Mandy Collier Director, Health Products and Food Branch
    Health Canada, Canada
  • Caroline  Croteau, PhD, RPh
    Caroline Croteau, PhD, RPh Country Safety Lead
    Pfizer Canada Inc, Canada
  • Deborah  Danoff, MD, FRCPC
    Deborah Danoff, MD, FRCPC Medical Evaluator
    Health Canada, Canada
  • Samar  Darwish, MBA, MSc
    Samar Darwish, MBA, MSc Director, Drug Regulatory Affairs
    Boehringer Ingelheim, Canada
  • Patrick  Fandja, MBA, MS
    Patrick Fandja, MBA, MS Director, Bureau of Biologics, Radiopharmaceuticals and Self-care products
    Health Canada, Canada
  • Fiona M Frappier, PhD
    Fiona M Frappier, PhD Senior Policy Analyst
    Health Canada, Canada
  • Agnes  Jankowicz, MS
    Agnes Jankowicz, MS Vice President, Pharmacovigilance
    Veristat, Canada
  • Yatika  Kohli, PhD, MBA
    Yatika Kohli, PhD, MBA Chief Regulatory and Strategy Officer
    NoNO Inc, Canada
  • Judith  Mergl, MSc
    Judith Mergl, MSc Director, Regulatory Affairs and Operational Services
    AbbVie Corporation, Canada
  • Kristin  Willemsen, MS
    Kristin Willemsen, MS Vice President, Scientific & Regulatory Affairs
    Food, Health & Consumer Products of Canada, Canada

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.